You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Canagliflozin (JNJ-28431754)

Showing 1 - 25 of 530
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diabetes Trial in India (Canagliflozin + Metformin HCl (Fixed Dose Combination))

Completed
  • Diabetes Mellitus
  • Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)
  • Bengaluru, India
  • +9 more
Aug 16, 2022

Heart Failure Trial in United States (Canagliflozin 100 mg, Placebo)

Completed
Has Results
  • Heart Failure
  • Canagliflozin 100 mg
  • Placebo
  • Fort Smith, Arkansas
  • +17 more
Dec 20, 2022

Diabetes, Type 2 Trial in Worldwide (Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo)

Recruiting
  • Diabetes Mellitus, Type 2
  • Canagliflozin 100 mg
  • +2 more
  • Little Rock, Arkansas
  • +121 more
Aug 18, 2022

Healthy Trial in Miramar (Canagliflozin (JNJ-28431754), Placebo)

Completed
  • Healthy
  • Canagliflozin (JNJ-28431754)
  • Placebo
  • Miramar, Florida
    (unnamed)
Dec 11, 2018

Diabetes, Type 2 Trial in Guadalajara, Mexico City, Monterrey (Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin)

Completed
Has Results
  • Diabetes Mellitus, Type 2
  • Canagliflozin 300 mg
  • +2 more
  • Guadalajara, Mexico
  • +4 more
Nov 11, 2019

Diabetes, Type 2 Trial in Decatur (canagliflozin, )

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Decatur, Georgia
    Atlanta VA Medical Center
Aug 12, 2022

Type 2 Diabetes, Diabetic Kidney Disease Trial in Aurora, Boston, Ann Arbor (canagliflozin, Aminohippurate Sodium Inj 20%)

Recruiting
  • Type 2 Diabetes
  • Diabetic Kidney Disease
  • Aurora, Colorado
  • +3 more
Aug 17, 2022

Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)

Not yet recruiting
  • Advanced Prostate Cancer
  • Lyon, France
  • +2 more
Oct 18, 2023

Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)

Not yet recruiting
  • Myeloproliferative Disorders
  • +3 more
  • (no location specified)
Nov 21, 2023

Lymphoma, Non-Hodgkin Trial (JNJ-87801493, JNJ-80948543, JNJ-75348780)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • (no location specified)
Nov 15, 2023

Diabetes, Type 2, Cardiovascular Diseases, Risk Factors Trial in Worldwide (Placebo, Canagliflozin (JNJ-28431754) 100 mg,

Completed
Has Results
  • Diabetes Mellitus, Type 2
  • +2 more
  • Placebo
  • +2 more
  • Birmingham, Alabama
  • +312 more
Nov 5, 2018

Pancreatic Cancer Trial in Hangzhou (Canagliflozin and Gemcitabine, Gemcitabine)

Not yet recruiting
  • Pancreatic Cancer
  • Hangzhou, Zhejiang, China
    Hangzhou first people's Hospital
Jun 11, 2023

Metastatic Castration-resistant Prostate Tumors Trial in Australia, Korea, Republic of, United States (JNJ-78278343, Cetrelimab)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Neoplasms
  • Sarasota, Florida
  • +7 more
Apr 6, 2023

Healthy Trial in Lincoln (JNJ-68179280, Placebo)

Recruiting
  • Healthy
  • Lincoln, Nebraska
    Celerion
Jan 17, 2023

Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,

Active, not recruiting
  • Prostatic Neoplasms
  • Metastatic Castration-Resistant Prostate Cancer
  • Abiraterone Acetate
  • +2 more
  • Los Angeles, California
  • +6 more
Jan 18, 2023

Type 2 Diabetes Trial in Nanjing (Mulberry Twig Alkaloid Tablet, Canagliflozin)

Active, not recruiting
  • Type 2 Diabetes Mellitus
  • Nanjing, China
    Jianhua Ma
May 3, 2023

Tumors, Solid Tumor, Adult, Non-Hodgkin Lymphoma Trial in Worldwide (JNJ-64619178)

Active, not recruiting
  • Neoplasms
  • +3 more
  • Sarasota, Florida
  • +17 more
Jan 27, 2023

Plaque Psoriasis Trial in United States (JNJ-77242113, Placebo)

Recruiting
  • Plaque Psoriasis
  • Rolling Meadows, Illinois
  • +8 more
Oct 18, 2023

Multiple Myeloma Trial in Belgium, Israel, Spain (Daratumumab, JNJ-63723283)

Completed
Has Results
  • Multiple Myeloma
  • Antwerpen, Belgium
  • +12 more
Dec 1, 2022

Healthy Trial in Leiden (JNJ-69095897, Placebo)

Recruiting
  • Healthy
  • Leiden, Netherlands
    Centre for Human Drug Research
Jan 31, 2023

Relapsed or Refractory Multiple Myeloma Trial in Worldwide (JNJ-79635322)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Edegem, Belgium
  • +16 more
Jan 27, 2023

Plaque Psoriasis Trial (JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib)

Not yet recruiting
  • Plaque Psoriasis
  • (no location specified)
Nov 16, 2023

Carcinoma, Non-small-Cell Lung Trial in New York, Fairfax (JNJ-86974680, Cetrelimab, Radiation Therapy)

Recruiting
  • Carcinoma, Non-small-Cell Lung
  • New York, New York
  • +1 more
Nov 8, 2023

Multiple Myeloma Trial in Japan, United States (JNJ-68284528)

Completed
  • Multiple Myeloma
  • JNJ-68284528
  • Phoenix, Arizona
  • +20 more
Oct 5, 2022

Tumor Trial in Chuo-Ku, Kashiwa (JNJ-63723283, Erdafitinib)

Completed
  • Neoplasm
  • Chuo-Ku, Japan
  • +1 more
Nov 3, 2022